Mechanism-Guided Development of Targeted Cancer Therapies

• 342 · PDF LYW-105：一种具有增强抗肿瘤疗效和更宽治疗指数的新型双特异性抗体偶联药物 LYW-105: A novel bispecific antibody-drug conjugate with enhanced antitumor efficacy and broader therapeutic index Qianqian Zhao, Zhangsheng Lu, Xun Cao, Xiaobing Tang, Liguo Wang, Peixiang Liu, Lu Wang, Jiajie Feng, Cexiong (Winston) Fu
• 343 · PDF BEN结构域蛋白4（BEND4）在前列腺癌（PCa）中的作用及沉默BEND4对PCa细胞系的影响 Role of BEN domain protein 4 (BEND4) in prostate cancer (PCa) and the effect of silencing BEND4 in PCa cell lines Janani Harikrishnan, Gnanasekar Munirathinam
• 344 · PDF TIP60通过减少顺铂-DNA加合物形成并增强其修复来介导化疗耐药 TIP60 mediates chemoresistance by reducing cisplatin-DNA adduct formation and enhancing their repair Madhavi P. Kadakia, Akshay Hira, Caroline McLaughlin, Michael Craig, Ramzi Nahhas, Jin Zhang, Mike Kemp
• 345 · PDF 通过工程化合成mRNA类似物在p53突变型癌症中恢复p53的治疗作用 Therapeutic restoration of p53 via engineered synthetic mRNA analogs in p53 mutant cancer Yong Ho Heo, Seung-Hyun Shin, Youngjin Han, Sol-Bi Shin, Innah Kim, Soye Jeon, Aran Park, Jooyun Byun, Daejin Kim, In Young Choi
• 346 · PDF TIP60在顺铂耐药的SCC中调控PTEN的表达、乙酰化和定位 TIP60 regulates PTEN expression, acetylation, and localization in cisplatin-resistant SCC Caroline McLaughlin, Akshay Hira, Madhavi Kadakia
• 347 · PDF 大细胞神经内分泌癌对Ras和ASCL1致癌通路的双重依赖 Dual dependency of large cell neuroendocrine carcinoma on Ras and ASCL1 oncogenic pathways Alyssa Cordes, Michael J. Peyton, Urooba Nadeem, Shreoshi Pal Choudhuri, Seth Hamilton, Shruti Raghavan, Kimberley Avila, Luc Girard, John D. Minna, Benjamin J. Drapkin
• 348 · PDF GFH603：一种分子胶样KEAP1-CUL3 E3连接酶复合物变构激活剂，用于靶向NRF2激活的肿瘤 GFH603: A molecular glue-like allosteric activator of the KEAP1-CUL3 E3 ligase complex for targeting NRF2-activated tumors Xiang Yu, Tao Jiang, Tao Liang, Feng Yan, Li Wang, Jingyang Zhang, Siyuan Le, Fusheng Zhou, Jiong Lan, Qiang Lu
• 349 · PDF 下一代测序和磷酸化激酶分析揭示CD74-ROS1融合中伴侣特异性的谱系特征 Next-generation sequencing and phospho-kinase analysis expose partner-specific profiles in CD74-ROS1 fusions Jasmine Vargas, Julia Olivieri, Georgios Pantouris
• 350 350 VHL缺失驱动的GCN5L1蓄积通过调控线粒体蛋白乙酰化和代谢重编程驱动透明细胞肾细胞癌 VHL loss-driven accumulation of GCN5L1 drives clear cell Renal Cell Carcinoma by regulating acetylation of mitochondrial proteins and metabolic reprogramming Bradley R. Webster, Kumarkrishna Raychaudhuri, Christopher Ricketts, W. Marston Linehan, Ramaprasad Srinivasan
• 352 · PDF 长链非编码RNA浆细胞瘤变异易位1的选择性剪接在前列腺癌发生中的作用 Long non coding RNA plasmacytoma variant translocation 1 alternative splicing in prostate carcinogenesis Seidu Adams, Dominique Weatherall, Rachel E. Bonacci, Chinedum Chukwuemeka Udekwu, Olorunseun O. Ogunwobi
• 353 353 种系BRCA2突变携带者中的胰腺癌建模 Pancreatic cancer modeling in germline BRCA2 mutation carriers Yi Xu, Nur Yucer, Alyssa Okimoto, Bobbie J. Rimel, Kate Lawrenson, Pei Wang, Simon A. Gayther
• 354 · PDF 靶向TROP2的ADC药物Dato-DXd和sac-TMT在大规模癌症细胞系panel中的不同应答特征 Distinct response profiles of TROP2-targeting ADCs Dato-DXd and sac-TMT across a large panel of cancer cell lines Janneke J. T. M. Melis, Eef F. P. Smits, Karsten P. F. van Doorn, Tsang W. Lam, Jeroen A. D. M. de Roos, Daphne J. F. Kluitmans, Jeffrey J. Kooijman, Guido J. R. Zaman, Jorg C. J. Benningshof
• 355 · PDF 溶瘤HSV-1中FIH1与IL-12的共表达阻断Notch信号并增强抗肿瘤免疫 Co-expression of FIH1 and IL-12 in oncolytic HSV-1 blocks Notch signaling and enhances anti-tumor immunity Karina Vazquez-Arreguin, Balveen Kaur
• 356 · PDF Rezatapopt联合KRAS抑制剂治疗TP53 Y220C和KRAS突变癌症 Rezatapopt and KRAS inhibitors for the treatment of TP53 Y220C and KRAS mutant cancers Argun Akcakanat, Ecaterina E. Dumbrava, Kurt W. Evans, Ran Zhang, Ming Zhao, Amber Kennon, Xiaofeng Zheng, Stephen M. Scott, Erkan Yuca, Gabriela Raso, Elisabeth K. Kong, Yasmeen Rizvi, David Hong, Masha V. Poyurovsky, Guillermina Lozano, Anil Korkut, Funda Meric-Bernstam
• 357 · PDF DIRAS3模拟肽在KRAS热点突变中实现MAPK和PI3K双通路抑制 DIRAS3 mimetic peptide achieves dual MAPK and PI3K pathway suppression across KRAS hotspot mutations Gamze Bildik, Junchen Liu, Weiqun Mao, Hailing Yang, John F. Hancock, Steven W. Millward, Robert C. Bast, Zhen Lu
• 358 · PDF 基于EV递送化学修饰siRNA在KRAS G12D突变胰腺癌中实现与MRTX1133相当的疗效 EV-based delivery of chemically modified siRNA achieves MRTX1133-comparable efficacy in KRAS G12D-mutant pancreatic cancer Hyo Kyeong kim, Yujeong Choi, Kyoung Hwa Kim, Jae Hwan Kim, Shung Hyun An, Dae Ho Bae, Minyoung Lee, Jihwa Chung, Seok-Hyun Kim, Kihwan Kwon
• 359 359 从DICER1综合征相关肉瘤的基因工程小鼠模型建立细胞系集合用于治疗评估 Development of a collection of cell lines from a genetically engineered mouse model of DICER1 syndrome-associated sarcoma for therapeutic assessment Lanlan Fang, Joyce Yu-Han Zhang, Shary Chen, Yannes Wai Yan Choi, Yemin Wang, David Huntsman
• 360 · PDF TM4SF1作为KRAS突变癌症有前景的ADC靶点 TM4SF1 as a promising ADC target for KRAS-mutated cancers Sewon Park, Youwon Lee, Jae-Sang Hwang, Ju-hyeon Lee, Mi Ran Yun, Byoung Chul Cho
• 362 · PDF 靶向RUNX转录活性可降低三阴性乳腺癌的肿瘤异质性和侵袭性 Targeting RUNX transcriptional activity reduces tumor heterogeneity and aggressiveness in triple-negative breast cancer Natalia Brenda Fernandez, Facundo Luis Couto, María Sofía Sosa, Natalia Rubinstein
• 363 · PDF 靶向胰腺导管腺癌中的支架/基质相关区域：一种新型咔唑衍生疗法 Targeting scaffold/matrix associated regions in pancreatic ductal adenocarcinoma: A novel carbazole-derived therapeutic Jack Prochnau, Daisy Medina, Jian Huang, Phat Do, Deepika Singh, Panneerdoss Subbarayallu, Stanton McHardy, Manjeet K. Rao
• 364 364 EMT驱动的改变促进对核激酶VRK1活性的依赖性，从而与免疫治疗在三阴性乳腺癌中产生协同作用 EMT-driven alterations promote dependency on nuclear kinase VRK1 activity to synergize with immune therapy in triple negative breast cancer Priyanka Sahu, Raymond Liu, Sergey Shmelkov, Uger Ozerdem, William C. Hahn, Jonathan So

在会议检索中浏览本分会场